GO:0062082 HLA-E specific inhibitory MHC class Ib receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0062082 describes a molecular function where a receptor binds HLA-E (a MHC class Ib molecule) to deliver an inhibitory signal in lymphocytes.
• The primary receptors carrying this activity are the NKG2A/CD94 heterodimer on NK cells and subsets of T cells.
• HLA-E presents a restricted set of peptides, often derived from the leader sequences of other HLA class I molecules, and its recognition is peptide-dependent.
• Engagement of HLA-E with NKG2A/CD94 inhibits NK cell cytotoxicity and cytokine production, a key mechanism of self-tolerance.
• Affinity and thermodynamics of NKG2x–HLA-E interactions vary, influencing the strength of inhibitory signaling.
• Dysregulation of HLA-E–NKG2A interactions has been linked to autoimmune conditions such as psoriasis.
Description
The term GO:0062082, HLA-E specific inhibitory MHC class Ib receptor activity, defines a molecular function in which a cell-surface receptor binds to HLA-E, a non-classical MHC class Ib molecule, and transduces a signal that suppresses lymphocyte activation. This activity is central to immune self-recognition and tolerance, allowing natural killer (NK) cells and certain T cell subsets to distinguish healthy cells from targets that have lost classical MHC class I expression. The receptor responsible for this function is typically the heterodimeric NKG2A/CD94 complex, which recognizes HLA-E in a peptide-dependent manner. Because HLA-E is often overexpressed in tumors and can be upregulated in autoimmune contexts, understanding this inhibitory axis is critical for cancer immunotherapy and autoimmunity research. Researchers studying this term aim to dissect how HLA-E–receptor interactions modulate immune responses, and how they can be targeted therapeutically.
HLA-E specific inhibitory MHC class Ib receptor activity At A Glance
| GO ID | GO:0062082 |
|---|---|
| GO term | HLA-E specific inhibitory MHC class Ib receptor activity |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to HLA-E to deliver an inhibitory signal in lymphocytes |
| Receptor complex | NKG2A/CD94 heterodimer (KLRD1/KLRC1) |
| Ligand | HLA-E (MHC class Ib) loaded with restricted peptides |
| Cell types | NK cells, subsets of T cells |
| Associated disease | Psoriasis, cancer immune evasion |
What Is GO:0062082?
In simple terms, GO:0062082 is the activity of a receptor that binds HLA-E and sends a 'do not attack' signal to immune cells. According to the QuickGO definition, it is a molecular function that combines with a MHC class Ib molecule of the HLA-A subclass to mediate signaling that inhibits activation of a lymphocyte. This function is attributed to receptors such as NKG2A/CD94, which are expressed on NK cells and some T cells.
Why Is HLA-E specific inhibitory MHC class Ib receptor activity Important in Cell Biology?
This molecular function is a cornerstone of immune tolerance and surveillance. By recognizing HLA-E, inhibitory receptors prevent NK cells from attacking healthy cells that display normal MHC class I levels. In cancer, tumor cells often overexpress HLA-E to engage NKG2A and evade immune destruction, making this pathway a prime target for checkpoint blockade. In autoimmunity, aberrant HLA-E–receptor interactions may contribute to disease pathogenesis, as suggested by genetic associations with psoriasis. Thus, understanding GO:0062082 is essential for developing therapies that modulate NK and T cell activity.
• Maintains self-tolerance by inhibiting NK cell activation against healthy cells.
• Regulates NK cell cytotoxicity and cytokine production.
• Modulates T cell responses in subsets expressing NKG2A.
• Implicated in cancer immune evasion through HLA-E overexpression.
• Associated with autoimmune diseases such as psoriasis.
• Provides a target for immune checkpoint inhibitors (e.g., anti-NKG2A).
• Influences transplantation outcomes via NK cell alloreactivity.
• Key to understanding pregnancy tolerance, as HLA-E is expressed on trophoblasts.
• Affinity differences among NKG2 receptors affect signaling strength.
• Potential biomarker for predicting response to immunotherapy.
Molecular Mechanism of HLA-E specific inhibitory MHC class Ib receptor activity
HLA-E peptide loading and surface presentation
In simple terms: HLA-E must carry a specific peptide to be recognized by the receptor.
HLA-E is a non-classical MHC class Ib molecule that binds a limited set of peptides, often derived from the leader sequences of other HLA class I molecules. This peptide loading is essential for stable HLA-E surface expression and recognition by NKG2A/CD94.
Receptor binding and affinity
In simple terms: The receptor NKG2A/CD94 binds to HLA-E with a certain strength.
The NKG2A/CD94 heterodimer binds HLA-E–peptide complexes with affinities that can vary depending on the peptide and the receptor. Thermodynamic studies show overlapping affinities among NKG2x receptors, which may fine-tune inhibitory signaling.
Intracellular signaling and inhibition
In simple terms: Once bound, the receptor sends a signal inside the cell to stop activation.
Ligation of NKG2A/CD94 by HLA-E leads to phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the cytoplasmic domain of NKG2A, recruiting phosphatases such as SHP-1 that dampen activating signals. This results in inhibition of NK cell cytotoxicity and cytokine release.
Regulation of receptor expression
In simple terms: The amount of receptor on the cell surface can change.
Expression of NKG2A and CD94 can be modulated by cytokines and activation status, influencing the strength of HLA-E-mediated inhibition. This regulation ensures context-dependent control of lymphocyte activation.
Key Genes Involved in GO:0062082 HLA-E specific inhibitory MHC class Ib receptor activity
The following genes encode the receptor complex, ligand, and associated signaling molecules central to GO:0062082.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KLRC1 (NKG2A) | Inhibitory receptor subunit that binds HLA-E | Target for checkpoint blockade; KO models to study NK cell education |
| KLRD1 (CD94) | Partner subunit of NKG2A; required for HLA-E binding | Essential for receptor surface expression; KO abolishes inhibitory signaling |
| HLA-E | Non-classical MHC class Ib ligand for NKG2A/CD94 | Overexpressed in tumors; KO to study immune evasion |
| HLA-A | Provides leader peptides for HLA-E loading | Affects HLA-E stability; KO alters peptide repertoire |
| HLA-B | Provides leader peptides for HLA-E loading | Similar to HLA-A; KO impacts HLA-E presentation |
| HLA-C | Provides leader peptides for HLA-E loading | Influences HLA-E surface levels; KO models |
| HLA-G | Non-classical MHC class I; can also bind ILT receptors | Modulates NK inhibition; KO to dissect pathways |
| KLRC2 (NKG2C) | Activating receptor that also binds HLA-E | Balances inhibition; KO to study activation |
| KLRC3 (NKG2E) | Activating receptor with affinity for HLA-E | Modulates NK activation; KO models |
| KLRC4 (NKG2F) | Receptor with unclear function | Potential regulatory role; KO studies |
| PTPN6 (SHP-1) | Phosphatase recruited by ITIMs | Mediates inhibitory signaling; KO enhances activation |
| PTPN11 (SHP-2) | Phosphatase involved in ITIM signaling | Modulates inhibition; KO models |
| TYROBP (DAP12) | Adaptor for activating NKG2 receptors | Counterbalances inhibition; KO alters signaling |
| HCST (DAP10) | Adaptor for activating receptors | Modulates NK activation; KO studies |
| B2M | Beta-2-microglobulin; required for MHC class I folding | KO abolishes HLA-E surface expression |
| TAP1 | Peptide transporter for MHC class I loading | KO affects HLA-E peptide loading |
| TAP2 | Peptide transporter for MHC class I loading | KO affects HLA-E peptide loading |
| TAPBP (Tapasin) | Peptide loading chaperone | KO alters HLA-E presentation |
How Is HLA-E specific inhibitory MHC class Ib receptor activity Regulated?
The activity of HLA-E specific inhibitory receptors is regulated at multiple levels. Receptor expression on NK cells and T cells can be modulated by cytokines such as IL-2 and TGF-beta, which influence NKG2A levels. Additionally, the availability of HLA-E–peptide complexes is controlled by peptide processing and loading machinery, including TAP and tapasin. Signaling strength is also tuned by the balance of activating and inhibitory receptors co-expressed on the same cell. Phosphatases like SHP-1 provide negative feedback within the signaling cascade.
HLA-E specific inhibitory MHC class Ib receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-E | Cancer immune evasion | HLA-E knockout tumor cells in syngeneic mouse models |
| KLRC1 (NKG2A) | Autoimmunity (psoriasis) | NKG2A knockout mice or human NK cells |
| KLRC2 (NKG2C) | Psoriasis susceptibility | NKG2C transgenic or knockout models |
| KLRD1 (CD94) | NK cell deficiency | CD94 knockout mice |
| PTPN6 (SHP-1) | Immune dysregulation | SHP-1 mutant mice (motheaten) |
HLA-E and cancer immune evasion
Many tumors overexpress HLA-E to engage NKG2A on NK and T cells, thereby evading immune attack. This interaction inhibits cytotoxic activity and promotes tumor progression. Blocking HLA-E–NKG2A with monoclonal antibodies has shown promise in restoring anti-tumor immunity.
Autoimmunity and psoriasis
Genetic variants in NKG2C and HLA-E have been associated with psoriasis, suggesting that dysregulated HLA-E–receptor interactions contribute to autoimmune skin inflammation. The inhibitory axis may fail to control autoreactive T cells, leading to tissue damage.
Transplantation and NK cell alloreactivity
In hematopoietic stem cell transplantation, mismatches in HLA-E and NKG2A can influence graft-versus-leukemia effects and graft rejection. Understanding these interactions helps predict outcomes and guide donor selection.
From HLA-E specific inhibitory MHC class Ib receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NKG2A mediate HLA-E-dependent inhibition? | NKG2A knockout (KO) in NK cell lines or primary NK cells |
| How does a point mutation in HLA-E affect receptor binding? | HLA-E point-mutation knock-in in tumor cells |
| Can we tag HLA-E to track its trafficking? | HLA-E tagged knock-in (e.g., GFP) |
| What is the effect of NKG2A overexpression? | NKG2A overexpression in NK cells or T cells |
| Which genes regulate HLA-E surface levels? | CRISPR library screening in MHC class I-deficient cells |
| Does CD94 deficiency abolish inhibitory signaling? | CD94 knockout mice |
How to Study the HLA-E specific inhibitory MHC class Ib receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Receptor expression and HLA-E binding | NK cell phenotyping |
| SPR | Binding affinity and thermodynamics | Receptor-ligand interaction studies |
| Immunoblotting | ITIM phosphorylation | Signaling activation |
| CRISPR screen | Genes affecting HLA-E presentation | Discovery of regulatory pathways |
| RNA-seq | Transcriptional changes upon receptor engagement | Global gene expression analysis |
| Mass spectrometry | HLA-E peptide repertoire | Immunopeptidomics |
| Confocal microscopy | Receptor-ligand co-localization | Imaging of immune synapse |
Flow cytometry and tetramer staining
HLA-E tetramers can be used to detect NKG2A/CD94 expression and binding on NK and T cells. This method allows quantification of receptor density and functional avidity.
Surface plasmon resonance (SPR)
SPR measures the affinity and kinetics of HLA-E binding to NKG2x receptors, revealing thermodynamic differences that impact signaling.
Phospho-ITIM immunoblotting
Following receptor engagement, phosphorylation of ITIMs on NKG2A can be assessed by immunoprecipitation and immunoblotting to confirm inhibitory signaling.
CRISPR knockout screens
Genome-wide CRISPR screens can identify genes that regulate HLA-E surface expression or NKG2A-mediated inhibition, uncovering novel modulators.
How CRISPR Can Be Used to Study GO:0062082 HLA-E specific inhibitory MHC class Ib receptor activity
Knockout
CRISPR knockout of KLRC1 (NKG2A) or KLRD1 (CD94) abolishes HLA-E-specific inhibitory activity, leading to enhanced NK cell cytotoxicity. This is used to study the role of the receptor in immune tolerance and cancer.
Point Mutation
Introducing point mutations in HLA-E or NKG2A can disrupt binding interfaces, allowing structure-function analysis of the interaction. Such models help identify critical residues for inhibitory signaling.
Knock-in
Knock-in of tagged HLA-E (e.g., GFP) enables real-time tracking of ligand trafficking and surface presentation. This approach is valuable for studying dynamic regulation.
Overexpression
Overexpression of NKG2A in NK or T cells can enhance inhibitory signaling and suppress activation, modeling conditions of immune evasion. This is used to test the sufficiency of the receptor.
How EDITGENE Supports HLA-E specific inhibitory MHC class Ib receptor activity Research
Researchers studying HLA-E specific inhibitory MHC class Ib receptor activity-related genes often need to determine whether a candidate gene is causally involved in immune regulation, and to dissect the precise molecular interactions. EDITGENE provides tailored CRISPR solutions to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for HLA-E specific inhibitory MHC class Ib receptor activity research.
Frequently Asked Questions About HLA-E specific inhibitory MHC class Ib receptor activity
What is HLA-E specific inhibitory MHC class Ib receptor activity?
It is a molecular function (GO:0062082) where a receptor binds HLA-E and delivers an inhibitory signal to lymphocytes, primarily through NKG2A/CD94.
What genes are involved in HLA-E specific inhibitory MHC class Ib receptor activity?
Key genes include KLRC1 (NKG2A), KLRD1 (CD94), and HLA-E itself, as well as peptide-loading genes like B2M, TAP1, and TAP2.
Which receptors bind HLA-E to inhibit immune cells?
The NKG2A/CD94 heterodimer is the main inhibitory receptor for HLA-E on NK cells and T cell subsets.
How does HLA-E inhibit NK cells?
HLA-E binding to NKG2A triggers ITIM phosphorylation and recruits phosphatases like SHP-1, which dampen activating signals.
What diseases are associated with HLA-E inhibitory signaling?
Cancer immune evasion and autoimmune diseases like psoriasis have been linked to dysregulated HLA-E–NKG2A interactions.
Can CRISPR be used to study HLA-E receptor activity?
Yes, CRISPR knockout of KLRC1 or KLRD1 abolishes inhibitory signaling, while knock-in of tagged HLA-E allows tracking.
What is the role of NKG2C in HLA-E recognition?
NKG2C is an activating receptor that also binds HLA-E, and its balance with NKG2A influences NK cell activation.
How is HLA-E peptide loading regulated?
HLA-E binds leader peptides from classical HLA class I molecules, a process dependent on TAP and tapasin.
What experimental models are used to study GO:0062082?
Common models include NK cell lines, primary NK cells, and knockout mice for KLRC1, KLRD1, or HLA-E.
Why is HLA-E specific inhibitory receptor activity important in cancer?
Tumors overexpress HLA-E to engage NKG2A and evade immune attack, making this pathway a target for checkpoint inhibitors.
Conclusion
GO:0062082, HLA-E specific inhibitory MHC class Ib receptor activity, is a fundamental molecular function that governs lymphocyte inhibition through HLA-E recognition. Its dysregulation contributes to cancer immune evasion and autoimmunity, and it represents a promising therapeutic target. Continued research using CRISPR models and advanced screening will further elucidate its mechanisms and clinical potential.
References
- 1. Pietra G et al.. 2009. HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells.. Curr Pharm Des 15(28):3336-44 PMID: 19860683
- 2. López-Botet M et al.. 2000. Paired inhibitory and triggering NK cell receptors for HLA class I molecules.. Hum Immunol 61(1):7-17 PMID: 10658973
- 3. Patel F et al.. 2013. NKG2C, HLA-E and their association with psoriasis.. Exp Dermatol 22(12):797-9 PMID: 24279916
- 4. Kaiser BK et al.. 2005. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics.. J Immunol 174(5):2878-84 PMID: 15728498
